Natco Pharma Q2 results 2026: profit down 61%
NATCO Pharma, a Hyderabad drug maker that also makes crop protection products, reported consolidated revenue from operations of Rs 967.3 crore and profit of Rs 202.6 crore for July to September 2026. The board also declared an interim dividend of Rs 1.25 per share.
Published 17 November 2026 · Potoos Research Services
The short answer. Revenue fell 29.0% from a year earlier and profit fell 60.9%. The company's press release says the fall in revenue is largely because of lower revenue from Lenalidomide, a cancer medicine, partly offset by growth in the rest of the business. The board declared a second interim dividend of Rs 1.25 per share, with a record date of Thursday 19 November 2026.
Quarter at a glance
Consolidated figures in Rs crore (the filing reports in Rs million; 10 million = 1 crore). Change compares the same quarter a year earlier.
| Measure | Jul-Sep 2026 | Jul-Sep 2025 | Change |
|---|---|---|---|
| Revenue from operations | 967.3 | 1,363.0 | -29.03% |
| Other income | 52.1 | 100.0 | -47.90% |
| Total expenses | 776.2 | 849.3 | -8.61% |
| Profit before tax and share of associate | 243.2 | 613.7 | -60.37% |
| Tax | 69.8 | 95.8 | -27.14% |
| Share of profit of associate | 29.2 | nil | n.a. |
| Profit for the period | 202.6 | 517.9 | -60.88% |
| Earnings per share (Rs) | 11.31 | 28.94 | -60.92% |
Source: NATCO unaudited consolidated financial results, PDF page 2. Percentages are recomputed from the filing figures in Rs million. "n.a." means a percent change cannot be worked out because there was no associate profit a year earlier. Profit for July to September 2025 belonging to the company's owners was Rs 518.4 crore; Rs 517.9 crore is the total.
Consolidated means NATCO together with its subsidiaries. An associate is a company in which NATCO holds a large stake but not control; NATCO adds only its share of that company's profit. Earnings per share is the profit divided by the number of shares.
Why did revenue and profit fall?
The press release enclosed with the filing says the fall from a year earlier "is largely attributable to lower Lenalidomide revenue in the current quarter which was partially offset by growth in the base business (including subsidiaries)." It does not give the Lenalidomide figure. Against the previous quarter (April to June 2026), revenue rose 31.6%, which the release puts down to "better performance in the International Formulation business."
Business split from the press release, in Rs crore. These totals include other income.
| Measure | Jul-Sep 2026 | Jul-Sep 2025 | Change |
|---|---|---|---|
| International formulations (incl. profit share and subsidiaries) | 668.4 | 1,140.2 | -41.38% |
| Domestic formulations | 145.7 | 105.4 | +38.24% |
| Active pharmaceutical ingredients | 61.3 | 53.9 | +13.73% |
| Crop health sciences | 61.0 | 52.4 | +16.41% |
| Other operating and non-operating income | 83.0 | 111.1 | -25.29% |
| Total | 1,019.4 | 1,463.0 | -30.32% |
Source: NATCO press release of 13 November 2026, PDF page 15. The segment table in the results shows the same picture: pharmaceuticals revenue fell 30.8% to Rs 906.3 crore, and agro chemicals revenue rose 16.2% to Rs 61.0 crore (segment reporting, PDF page 5).
Other lines that moved
Other income fell 47.9% to Rs 52.1 crore. The filing does not explain the fall. Finance costs rose 34.4% to Rs 17.6 crore; the filing does not explain this either.
Tax. Tax took 28.7% of profit before tax this quarter, against 15.6% a year earlier. In July to September 2025 the company booked a deferred tax credit of Rs 44.6 crore, which lowered that quarter's tax. Note 7 says NATCO moved to the lower 22% tax rate under section 115BAA from 2026-27 and re-measured its deferred tax, booking Rs 115 crore as a deferred tax asset during the year ended 31 March 2026. The filing does not say how much of that fell in July to September 2025.
Associate profit. NATCO's share of profit from Adcock Ingram Holdings, a South African company, was Rs 29.2 crore. There was none a year earlier because Adcock became an associate from 11 November 2025. Note 8 says NATCO's South African subsidiary bought a further 13.25% of Adcock for ZAR 1,814.74 million (Rs 1,060 crore), completed on 14 July 2026. The press release says this took NATCO's holding to 49%.
Rights issue and demerger
A rights issue lets existing shareholders apply for new shares in proportion to what they already hold. Note 9 says NATCO's fund raising committee approved 1,70,58,082 new shares of face value Rs 2 at Rs 750 each (a premium of Rs 748), in the ratio of 2 new shares for every 21 held on the record date of 1 October 2026. The shares were allotted on 23 October 2026, after the quarter ended. At Rs 750 a share, that is about Rs 1,279 crore (our arithmetic: shares multiplied by price).
Note 6 says the board approved on 24 March 2026 a plan to demerge the agro chemical business into NATCO Crop Health Sciences Limited. A demerger moves a business into a separate company. On 9 September 2026 the board decided to change the plan so that the share swap ratio stays the same after the rights issue. The company says it is filing the revised plan with the authorities for approval.
Did the board declare a dividend?
Yes. The board declared a second interim dividend of Rs 1.25 per equity share of face value Rs 2 (62.50% of face value) for 2026-27. The record date is Thursday, 19 November 2026. The record date is the day the company checks its list of shareholders to decide who gets the dividend. Payment will start from Friday, 27 November 2026. The first interim dividend for 2026-27 was Rs 1.50 per share, approved on 14 August 2026. Check NSE's corporate actions page for the ex-date. Source: outcome letter, PDF page 1 and note 10, PDF page 6.
Standalone results and the auditor
Standalone figures cover NATCO on its own. Standalone profit was Rs 143.2 crore, down 71.4% from Rs 500.9 crore, and below the consolidated figure (note 5, PDF page 6). The statutory auditor, B S R and Co, carried out a limited review. A limited review is a lighter check than a full audit. Note 3 says the auditor issued an unmodified review report, which means it did not report a problem with the figures.
Sources
- NATCO Pharma outcome of board meeting with unaudited standalone and consolidated financial results for the quarter and half year ended 30 September 2026, and press release. 13 November 2026. PDF page 1, outcome letter; page 2, consolidated results; page 5, segment reporting; page 6, notes to consolidated results; pages 7 to 9, review report on consolidated results; page 10, standalone results; pages 15 and 16, press release.
Data source: the data on this page is referenced from NSE (National Stock Exchange of India), nseindia.com. The documents are linked in the Sources list above. NSE has not reviewed or approved this page.
Sources checked on 16 November 2026. Information cutoff: 16 November 2026, 15:00 IST
Common questions
Why did Natco Pharma profit fall in Q2 FY27?
Revenue fell 29% from a year earlier. The company's press release says this is largely because of lower Lenalidomide revenue, partly offset by growth in the rest of the business.
What dividend did Natco Pharma declare with its Q2 results?
A second interim dividend of Rs 1.25 per share of face value Rs 2 for 2026-27. The record date is 19 November 2026 and payment starts from 27 November 2026.
What is the Natco Pharma rights issue?
Note 9 says 1,70,58,082 new shares at Rs 750 each, 2 for every 21 held on 1 October 2026, allotted on 23 October 2026.
Potoos Research, SEBI-registered Research Analyst. Registration number INH000027380. SEBI is the Securities and Exchange Board of India.
